| 2025-08-08 | +30.8% | earnings | Seeking Alpha | Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth |
| 2025-08-08 | +30.8% | earnings | Seeking Alpha | Artivion, Inc. (AORT) Q2 2025 Earnings Call Transcript |
| 2025-08-08 | +30.8% | news | Yahoo Finance | Why Is Artivion (AORT) Stock Rocketing Higher Today - Yahoo Finance |
| 2025-08-07 | +26.2% | earnings | Seeking Alpha | Artivion Non-GAAP EPS of $0.24 beats by $0.11, revenue of $113M beats by $5.05M |
| 2025-08-07 | +26.2% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2021-04-29 | +23.6% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2025-05-06 | +19.8% | earnings | Seeking Alpha | Artivion raises 2025 revenue guidance to $423M-$435M with focus on AMDS and On-X opportunities |
| 2025-05-06 | +19.8% | earnings | Seeking Alpha | Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript |
| 2025-05-06 | +19.8% | executive | simplywall.st | Artivion, Inc.'s (NYSE:AORT) CEO Looks Like They Deserve Their Pay Packet - simplywall.st |
| 2025-05-05 | +18.9% | earnings | Seeking Alpha | Artivion Non-GAAP EPS of $0.06 beats by $0.02, revenue of $99M beats by $4.19M |
| 2025-05-05 | +18.9% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2024-05-06 | +12.4% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2023-05-04 | +11.6% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2026-02-13 | -10.4% | earnings | Seeking Alpha | Artivion outlines 2026 revenue growth target of 10% to 14% with strong AMDS and On-X momentum |
| 2026-02-13 | -10.4% | earnings | Seeking Alpha | Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript |
| 2026-02-13 | -10.4% | news | Yahoo Finance | Artivion (AORT) Stock Trades Down, Here Is Why - Yahoo Finance |
| 2026-02-13 | -10.4% | analyst | Investing.com | Canaccord Genuity lowers Artivion stock price target to $48 on market compression - Investing.com |
| 2025-02-24 | -8.6% | earnings | Seeking Alpha | Artivion Non-GAAP EPS of $0.00 misses by $0.04, revenue of $97.31M misses by $3.51M |
| 2025-02-24 | -8.6% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2025-02-25 | -8.3% | earnings | Seeking Alpha | Artivion, Inc. 2024 Q4 - Results - Earnings Call Presentation |
| 2025-02-25 | -8.3% | earnings | Seeking Alpha | Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript |
| 2025-02-25 | -8.3% | earnings | GuruFocus | Artivion (AORT) Shares Drop After Weak Q4 2024 Results - GuruFocus |
| 2023-11-02 | +7.6% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2022-05-05 | -7.3% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2026-02-12 | -7.3% | earnings | Seeking Alpha | Artivion Non-GAAP EPS of $0.17 misses by $0.01, revenue of $116M misses by $0.41M |
| 2026-02-12 | -7.3% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2026-02-12 | -7.3% | news | PR Newswire | Artivion Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire |
| 2025-11-07 | -7.0% | earnings | Seeking Alpha | Artivion outlines double-digit revenue growth target for 2025 as AMDS and On-X momentum builds |
| 2025-11-07 | -7.0% | earnings | Seeking Alpha | Artivion, Inc. (AORT) Q3 2025 Earnings Call Transcript |
| 2024-02-15 | +6.9% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2025-08-11 | +6.2% | legal | SEC EDGAR | AORT 8-K: 5.02 (SEC Filing) |
| 2023-02-16 | +6.0% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2022-09-01 | -5.7% | analyst | TradingView | AORT Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-11-11 | +5.6% | earnings | Seeking Alpha | Artivion, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2026-04-07 | +5.2% | news | StockStory | Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know |
| 2026-04-07 | +5.2% | news | StockStory | Stocks making big moves yesterday: Levi's, Strategy, Vishay Precision, Celsius, and Artivion |
| 2026-04-07 | +5.2% | legal | MT Newswires | Sector Update: Health Care Stocks Mixed Premarket Tuesday |
| 2026-04-07 | +5.2% | M&A | MT Newswires | Artivion Says FDA Approves NEXUS Aortic Arch System, Secures Option to Acquire Endospan |
| 2026-04-07 | +5.2% | legal | PR Newswire | Artivion Announces U.S. FDA Approval of the NEXUS® Aortic Arch System |
| 2026-04-07 | +5.2% | legal | Stock Titan | FDA approved a less invasive aortic arch device for high-risk patients - Stock Titan |
| 2026-04-07 | +5.2% | analyst | GuruFocus | Artivion (AORT) Receives "Buy" Rating Reiteration from Needham | - GuruFocus |
| 2025-08-10 | +5.1% | news | StocksToTrade | Artivion Surges on Improved 2025 Financial Outlook - StocksToTrade |
| 2022-01-25 | -4.7% | news | Zacks Investment Research | Should I buy Artivion (AORT) - Zacks Investment Research |
| 2025-10-01 | -4.6% | news | TradingKey | AORT|Artivion Inc|Price:37.740|Chg%:0.58 - TradingKey |
| 2024-01-18 | -4.1% | legal | SEC EDGAR | AORT 8-K: 1.01, 2.03 (SEC Filing) |
| 2024-08-08 | -4.0% | earnings | Seeking Alpha | Artivion Non-GAAP EPS of $0.07 beats by $0.04, revenue of $98M beats by $0.4M |
| 2024-08-08 | -4.0% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2024-11-07 | -3.7% | earnings | Seeking Alpha | Artivion Non-GAAP EPS of $0.12 beats by $0.11, revenue of $95.8M beats by $1.04M |
| 2024-11-07 | -3.7% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2021-11-04 | +3.5% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2022-02-02 | -3.3% | earnings | MarketBeat | Artivion (AORT) Stock Price, News & Analysis $AORT - MarketBeat |
| 2025-09-15 | -3.2% | legal | SEC EDGAR | AORT 8-K: 1.01, 2.03 (SEC Filing) |
| 2025-08-21 | +3.1% | news | simplywall.st | This Insider Has Just Sold Shares In Artivion - simplywall.st |
| 2022-02-17 | +2.7% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2024-12-26 | +2.6% | news | Seeking Alpha | Artivion: Current Valuation Seems Stretched |
| 2026-04-03 | -2.6% | news | Xã Châu Thành | AORT Stock Analysis: Artivion Inc. Medical Device Stock Trades Flat Near 34.17 - Xã Châu Thành |
| 2026-04-06 | +2.6% | news | Yahoo Finance | Why Artivion (AORT) Stock Is Down Today - Yahoo Finance |
| 2026-04-06 | +2.6% | news | The Globe and Mail | Why Artivion (AORT) Stock Is Down Today - The Globe and Mail |
| 2026-04-06 | +2.6% | earnings | MarketBeat | SG Americas Securities LLC Raises Stake in Artivion, Inc. $AORT - MarketBeat |
| 2025-11-06 | -2.6% | earnings | Seeking Alpha | Artivion Non-GAAP EPS of $0.16 beats by $0.01, revenue of $113.4M beats by $2.81M |
| 2025-11-06 | -2.6% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2023-08-03 | -2.5% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2025-10-21 | +2.5% | earnings | DirectorsTalk Interviews | Artivion, Inc. (AORT) Stock Analysis: Navigating Growth With A 15.3% Revenue Surge - DirectorsTalk Interviews |
| 2022-01-20 | +2.5% | legal | SEC EDGAR | AORT 8-K: 5.03, 8.01 (SEC Filing) |
| 2026-02-02 | +2.5% | news | Stock Titan | 94% survival, 91% stroke-free in Artivion aortic trials - Stock Titan |
| 2025-09-29 | +2.5% | legal | SEC EDGAR | AORT 8-K: 1.01 and (SEC Filing) |
| 2022-11-03 | -2.3% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2026-04-20 | -2.2% | legal | Sahm | Will FDA Approval Of NEXUS And Endospan Option Reshape Artivion's (AORT) Minimally Invasive Aortic Strategy - Sahm |
| 2026-03-04 | -2.1% | news | Investing.com | Artivion (AORT) CCO Davis sells $172k in shares to cover tax obligations - Investing.com |
| 2021-06-02 | -2.1% | legal | SEC EDGAR | AORT 8-K: 1.01 (SEC Filing) |
| 2025-10-29 | +1.9% | earnings | Yahoo Finance | Strong Results and Improved Guidance Lifted Artivion (AORT) - Yahoo Finance |
| 2025-05-28 | +1.9% | news | PR Newswire | Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock - PR Newswire |
| 2021-09-22 | -1.7% | legal | SEC EDGAR | AORT 8-K: 5.02 and (SEC Filing) |
| 2026-02-19 | +1.7% | earnings | simplywall.st | We Think Artivion's (NYSE:AORT) Profit Is Only A Baseline For What They Can Achieve - simplywall.st |
| 2022-09-29 | -1.7% | legal | SEC EDGAR | AORT 8-K: 5.02 (SEC Filing) |
| 2022-02-03 | +1.7% | news | Stock Titan | Latest AORT News - Artivion Announces Release Date and Telecon... - Stock Titan |
| 2026-04-23 | +1.6% | news | PR Newswire | Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results |
| 2026-04-23 | +1.6% | earnings | Stock Titan | Artivion's next earnings update lands May 7, with a 4:30 p.m. ET webcast - Stock Titan |
| 2026-04-23 | +1.6% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | AORT (Artivion Inc.) shares fall 1.26% after Q4 2025 EPS lands 40% below consensus analyst estimates. - Social Investment Platform - Cổng thông tin điện tử tỉnh Lào Cai |
| 2022-08-04 | -1.5% | legal | SEC EDGAR | AORT 8-K: 2.02 and (SEC Filing) |
| 2022-08-04 | -1.5% | news | TradingView | AORT Stock Price and Chart — NYSE:AORT - TradingView |
| 2026-04-11 | +1.5% | earnings | MarketBeat | Tudor Investment Corp ET AL Sells 39,388 Shares of Artivion, Inc. $AORT - MarketBeat |
| 2024-12-23 | -1.5% | legal | SEC EDGAR | AORT 8-K: 8.01 and (SEC Filing) |
| 2025-09-10 | -1.5% | news | Seeking Alpha | Artivion, Inc. (AORT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) |
| 2024-05-11 | -1.4% | earnings | MarketBeat | Artivion (AORT) Stock Forecast and Price Target 2026 $AORT - MarketBeat |
| 2024-12-09 | +1.4% | legal | SEC EDGAR | AORT 8-K: 8.01 and (SEC Filing) |
| 2021-07-29 | +1.4% | legal | SEC EDGAR | AORT 8-K: 1.01, 2.02, 7.01 (SEC Filing) |
| 2026-04-13 | -1.4% | news | StockStory | 1 Stock Under $50 to Own for Decades and 2 We Avoid |
| 2026-03-26 | +1.2% | news | Stock Titan | Vanguard reports 0 AORT shares after internal realignment (NASDAQ: AORT) - Stock Titan |
| 2025-03-04 | +1.1% | news | Stock Titan | When Will Artivion Reveal Its Latest Cardiac Surgery Innovations? Key Conference Date Set - Stock Titan |
| 2024-08-10 | +1.1% | earnings | Seeking Alpha | Artivion, Inc. 2024 Q2 - Results - Earnings Call Presentation |
| 2024-08-10 | +1.1% | earnings | Seeking Alpha | Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript |
| 2023-12-06 | +1.1% | legal | SEC EDGAR | AORT 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-22 | +1.0% | earnings | MarketBeat | Artivion, Inc. (NYSE:AORT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat |
| 2026-04-22 | +1.0% | earnings | Cổng thông tin điện tử Tỉnh Sơn La | Artivion (AORT) Stock: Price Action Overview | Artivion posts 40% EPS miss below Street estimates - Global Trading Community - Cổng thông tin điện tử Tỉnh Sơn La |
| 2024-10-23 | +1.0% | analyst | Seeking Alpha | Artivion started at market outperform by JMP, stent graft devices cited |
| 2022-10-17 | -1.0% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Artivion (AORT) - Zacks Investment Research |
| 2024-06-21 | +0.9% | news | Seeking Alpha | Data-Driven Growth Fuels More Upside For Overlooked Artivion |
| 2025-05-29 | -0.9% | legal | SEC EDGAR | AORT 8-K: 3.02, 8.01 (SEC Filing) |
| 2024-07-01 | -0.9% | expansion | Seeking Alpha | Artivion amends agreements with Endospan |
| 2024-07-01 | -0.9% | legal | SEC EDGAR | AORT 8-K: 1.01, 7.01 (SEC Filing) |
| 2024-03-13 | +0.9% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-04-16 | -0.8% | analyst | Simply Wall St. | How The Investment Story Is Shifting For Artivion (AORT) After Recent Analyst And FDA Updates |
| 2026-04-16 | -0.8% | news | UBND thành phố Hải Phòng | Artivion (AORT) Stock: Why It Matters This Year (-1.95%) 2026-04-16 - Crowd Risk Alerts - UBND thành phố Hải Phòng |
| 2025-06-03 | -0.7% | legal | Stock Titan | Artivion Sets Double Conference Appearance: Truist Securities and Citizens Medical Forum Coming Up - Stock Titan |
| 2026-03-27 | -0.7% | news | StockStory | Artivion, Intuitive Surgical, GE HealthCare, LeMaitre, and Globus Medical Shares Plummet, What You Need To Know - StockStory |
| 2025-09-03 | -0.7% | news | Seeking Alpha | Share Growth And Strong Clinical Results Continue To Support The Artivion Story |
| 2026-04-08 | +0.5% | legal | Zacks | Artivion Secures FDA Approval for NEXUS Aortic Arch System |
| 2026-04-08 | +0.5% | news | Zacks | Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? |
| 2026-04-08 | +0.5% | news | Yahoo Finance | Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance |
| 2024-11-09 | +0.5% | earnings | Seeking Alpha | Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript |
| 2026-02-16 | -0.4% | earnings | Seeking Alpha | Artivion, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2025-05-14 | -0.4% | expansion | Seeking Alpha | Artivion enter $95M exchange agreement |
| 2025-05-14 | -0.4% | legal | SEC EDGAR | AORT 8-K: 3.02, 8.01 (SEC Filing) |
| 2025-12-29 | -0.2% | news | Seeking Alpha | Artivion Continues Building Toward Bigger And Better Things |
| 2025-12-29 | -0.2% | news | Seeking Alpha | Artivion Continues Building Toward Bigger And Better Things (NYSE:AORT) - Seeking Alpha |
| 2026-03-03 | +0.1% | executive | Investing.com | Mackin James P, Artivion CEO, sells $566k in AORT stock - Investing.com |